Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly and Company (NYSE: LLY) announced that new data from its monarchE study will be presented at the European Society for Medical Oncology (ESMO) Virtual Plenary on October 14, 2021. The study focuses on the investigational use of Verzenio (abemaciclib) combined with endocrine therapy for patients with HR+, HER2- high-risk early breast cancer. In total, 5,637 patients were randomized to receive either Verzenio with standard endocrine therapy or standard endocrine therapy alone, aiming to evaluate invasive disease-free survival and other key outcomes.
Eli Lilly (NYSE: LLY) is recalling lot D239382D of its Glucagon Emergency Kit due to a complaint that the vial contained liquid instead of the intended powder form. This issue may lead to decreased effectiveness in treating severe hypoglycemia, posing serious health risks including seizures. The recall was initiated after a patient experienced a lack of drug effect and subsequent seizures. Distribution of the affected lot has been ceased, and return and replacement measures are underway for consumers and wholesalers.
Eli Lilly announced the pricing terms for its cash tender offer for specific outstanding debt securities, totaling up to $1.5 billion. The offer allows holders of eligible notes to receive a total consideration based on a reference yield plus a fixed spread, including an early tender premium of $30 per $1,000 of principal. The offer expires on October 4, 2021. Notably, the previously set maximum purchase limits for the 3.950% and 4.150% notes have been removed, enhancing liquidity. The anticipated settlement date is September 22, 2021.
Eli Lilly (NYSE: LLY) announced a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of bamlanivimab and etesevimab for COVID-19 treatment in patients aged 12 and older. This agreement enables EU countries to purchase these treatments directly, enhancing access before formal marketing authorization. Bamlanivimab and etesevimab have shown efficacy against COVID-19 variants like Delta. Although some countries have already ordered doses, this agreement allows for additional supplies as needed. Lilly does not anticipate a change to its 2021 financial guidance.
Eli Lilly and Company (NYSE: LLY) announced the early tender results of its cash tender offer for up to $1.5 billion in outstanding debt securities. The result showed that $2,016,575,000 in notes were validly tendered before the early tender date of September 20, 2021. Notably, Lilly removed the previously announced caps on its 4.150% Notes due 2059 and 3.950% Notes due 2049, allowing for larger acceptance amounts. The settlement date for accepted notes is set for September 22, 2021, and the tender offer is expected to expire on October 4, 2021.
The FDA has expanded the Emergency Use Authorization (EUA) for Eli Lilly's bamlanivimab and etesevimab to include post-exposure prophylaxis for COVID-19. This authorization targets high-risk individuals aged 12 and older who are either unvaccinated or might not respond adequately to vaccination. Data from the BLAZE-2 study indicated that bamlanivimab significantly reduced symptomatic COVID-19 risk in nursing home residents. Since the pandemic's onset, over 535,000 treatment courses have been provided, helping avert thousands of hospitalizations and deaths.
Eli Lilly and Company (NYSE: LLY) announced a contract with the U.S. government to supply 388,000 doses of etesevimab, which will complement previously purchased bamlanivimab doses. This agreement is expected to generate approximately $330 million in revenue during the second half of 2021. The rise in COVID-19 cases has driven increased demand for monoclonal antibody therapies like these, especially in areas with low vaccination rates. Shipments of the doses are scheduled for Q3 and Q4 2021.
Eli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021. Patrik Jonsson, senior vice president and president of Lilly Immunology, will engage in a virtual fireside chat at 1:20 p.m. ET. Interested parties can access a live audio webcast on Lilly's Investor website, with a replay available for 90 days.
Lilly is dedicated to advancing healthcare through innovative medicines and remains committed to its founding mission of improving lives globally.
New research from Eli Lilly Company (NYSE: LLY) will be showcased at the ESMO Congress 2021 (September 16-21). Key findings include:
- Verzenio: Studies on high-risk early breast cancer and advanced breast cancer.
- Retevmo: Real-world data on medullary thyroid cancer and RET testing patterns in Europe.
- CYRAMZA: Insights on metastatic NSCLC and the impact of TP53 status.
- Sintilimab: Phase III trial results for esophageal and gastric cancers.
Posters available starting September 16, with mini-oral presentations on September 17.
Summary not available.